TSC22D1

Across TCGA pan-cancer cohorts, TSC22D1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TSC22D1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TSC22D1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TSC22D1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, DLBC, and HNSC are the cancer types where TSC22D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
HNSC	OS	Median	II,III,IV	0.058	0.712	<.001	24	view →
LIHC	OS	Median	All	0.014	0.787	<.001	12	view →
SKCM	OS	Median	All	0.257	0.781	.015	9	view →
BRCA	OS	Median	III,IV	0.111	0.544	.029	6	view →
PRAD	DFS	Median	All	0.617	0.886	.041	6	view →
UCEC	DFS	Median	All	0.935	0.609	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TSC22D1–MESO (OS)

Open the MESO breakdown →